|
US2957906A
(en)
|
1955-10-25 |
1960-10-25 |
Monsanto Chemicals |
Ketones
|
|
US3227473A
(en)
|
1963-12-12 |
1966-01-04 |
Julian S Halbern |
Check identification
|
|
JPS5752354B2
(enExample)
|
1973-10-22 |
1982-11-06 |
|
|
|
JPS5069091U
(enExample)
|
1973-10-25 |
1975-06-19 |
|
|
|
US3980674A
(en)
|
1974-01-28 |
1976-09-14 |
Delmar Chemicals Limited |
2,3-Disubstituted 7-oxabicyclo-[2.2.1]-5-heptene
|
|
JPS5132733A
(en)
|
1974-09-10 |
1976-03-19 |
Kyowa Hakko Kogyo Kk |
Josozai |
|
US3954913A
(en)
|
1975-01-06 |
1976-05-04 |
The Standard Oil Company |
Stabilized nitrile polymers
|
|
JPS5188631U
(enExample)
|
1975-01-10 |
1976-07-15 |
|
|
|
JPS5188631A
(en)
|
1975-01-31 |
1976-08-03 |
|
Hiiryoyosatsukinzai oyobi sonoseizoho
|
|
US4143054A
(en)
|
1977-11-04 |
1979-03-06 |
E. R. Squibb & Sons, Inc. |
7-oxabicycloheptane- and 7-oxabicycloheptene compounds
|
|
US4218478A
(en)
|
1979-01-05 |
1980-08-19 |
Ruiko Oiwa |
Trichostatin as an antiprotozoal agent
|
|
US4760067A
(en)
|
1979-08-15 |
1988-07-26 |
Merck & Co., Inc. |
Allylsulfoxide enzyme inhibitors
|
|
US4298752A
(en)
|
1980-09-19 |
1981-11-03 |
Regents Of The University Of California |
Cycloadduct precursors of cantharidin and method
|
|
US4614825A
(en)
|
1982-05-17 |
1986-09-30 |
E. R. Squibb & Sons, Inc. |
7-oxabicycloheptane and 7-oxabicycloheptene compounds
|
|
US4463015A
(en)
|
1982-08-18 |
1984-07-31 |
E. R. Squibb & Sons, Inc. |
Aryl substituted 7-oxabicycloheptane compounds, useful in inhibiting platelet aggregation
|
|
US4518696A
(en)
|
1983-01-11 |
1985-05-21 |
Chr. Hansen's Laboratory, Inc. |
Stabilized liquid bacterial suspension for oral administration to animals
|
|
US4524151A
(en)
|
1983-11-14 |
1985-06-18 |
E. R. Squibb & Sons, Inc. |
7-Oxabicycloheptane thio ethers useful as cardiovascular agents
|
|
JPS61176523A
(ja)
|
1985-01-30 |
1986-08-08 |
Teruhiko Beppu |
制癌剤
|
|
US4654355A
(en)
|
1985-08-01 |
1987-03-31 |
E. R. Squibb & Sons, Inc. |
7-oxabicycloheptane substituted amide-thioamide prostaglandin analogs
|
|
US4816579A
(en)
|
1986-06-04 |
1989-03-28 |
E. R. Squibb & Sons, Inc. |
7-oxabicycloheptane amino-alcohol intermediates useful in making thromboxane A2 receptor antagonists
|
|
US4851553A
(en)
|
1986-06-04 |
1989-07-25 |
E. R. Squibb & Sons, Inc. |
7-oxabicycloheptane amido-carboxylic acids
|
|
US4851423A
(en)
|
1986-12-10 |
1989-07-25 |
Schering Corporation |
Pharmaceutically active compounds
|
|
SU1553533A1
(ru)
|
1988-01-28 |
1990-03-30 |
Военная Краснознаменная академия химической защиты им.Маршала Советского Союза С.К.Тимошенко |
Способ получени 1,4-бисполифторалкил-7-оксбицикло [2.2.1]гептанов
|
|
JP2789365B2
(ja)
|
1988-12-14 |
1998-08-20 |
塩野義製薬株式会社 |
ジカルボン酸モノエステルおよびその製造法
|
|
RU2015980C1
(ru)
|
1990-02-06 |
1994-07-15 |
Е.Р.Сквибб энд Санз, Инк. |
7-оксабициклогептилзамещенные гетероциклические амиды или их стереоизомеры в качестве антагонистов рецепторов тромбоксана
|
|
US5763647A
(en)
|
1990-03-30 |
1998-06-09 |
Shionogi & Co., Ltd. |
Preparation of optically active 1,4-bridged-cyclohexane carboxylic acid derivatives
|
|
CA2084412C
(en)
|
1990-06-04 |
2000-05-09 |
W. Stephen Faraci |
Pyrrolidine and thiazolidine amides
|
|
US5229115A
(en)
|
1990-07-26 |
1993-07-20 |
Immunex Corporation |
Adoptive immunotherapy with interleukin-7
|
|
US5266710A
(en)
|
1990-12-18 |
1993-11-30 |
Patel Ramesh N |
(Exo,exo)-7-oxabicyclo[2.2.1]heptane-2,3-dimethanol; monoacyl ester and diacyl ester
|
|
US5206386A
(en)
|
1991-03-20 |
1993-04-27 |
Isp Investments Inc. |
Controlled release N-substituted pyrrolidone esters and process for the use thereof
|
|
US5580858A
(en)
|
1991-06-10 |
1996-12-03 |
Alberta Research Council |
Immunosuppressive and tolerogenic modified Lewisx compounds
|
|
JP3134233B2
(ja)
|
1991-07-26 |
2001-02-13 |
株式会社林原生物化学研究所 |
α−グリコシル ケルセチンとその製造方法並びに用途
|
|
US5326898A
(en)
|
1992-02-11 |
1994-07-05 |
Allergan, Inc. |
Substituted phenylethenyl compounds having retinoid-like biological activity
|
|
US6602713B1
(en)
|
2001-02-09 |
2003-08-05 |
Isis Pharmaceuticals, Inc. |
Antisense modulation of protein phosphatase 2 catalytic subunit beta expression
|
|
US5580856A
(en)
|
1994-07-15 |
1996-12-03 |
Prestrelski; Steven J. |
Formulation of a reconstituted protein, and method and kit for the production thereof
|
|
US5518993A
(en)
|
1994-08-12 |
1996-05-21 |
Buckman Laboratories International, Inc. |
Pesticidal compositions containing ethoxylated fatty amines for increasing the effectiveness of endothal and salts thereof
|
|
US5770382A
(en)
|
1994-12-30 |
1998-06-23 |
Ligand Pharmaceuticals, Inc. |
Tricyclic retinoids, methods for their production and use
|
|
US6222055B1
(en)
|
1995-07-06 |
2001-04-24 |
Fraunhofer-Gesellschaft Zur Foerderung Der Angwandten Forschung E.V. |
Hydrolyzable and polymerizable and/or polyadditive silanes
|
|
DE19600707B4
(de)
|
1996-01-11 |
2004-02-19 |
Glüsenkamp, Karl-Heinz, Dr. |
Biyclische Anhydrid-Wirkstoff-Verbindungen, Verfahren zur Herstellung und Verwendung derselben
|
|
US5968965A
(en)
|
1996-01-30 |
1999-10-19 |
Merck & Co., Inc. |
Inhibitors of farnesyl-protein transferase
|
|
US6777217B1
(en)
|
1996-03-26 |
2004-08-17 |
President And Fellows Of Harvard College |
Histone deacetylases, and uses related thereto
|
|
US5925651A
(en)
|
1996-04-03 |
1999-07-20 |
Merck & Co., Inc. |
Inhibitors of farnesyl-protein transferase
|
|
US6387673B1
(en)
|
1997-05-01 |
2002-05-14 |
The Salk Institute For Biological Studies |
Compounds useful for the modulation of processes mediated by nuclear hormone receptors, methods for the identification and use of such compounds
|
|
EP1391206B1
(en)
|
1997-10-15 |
2008-07-02 |
Polarx Biopharmaceuticals, Inc. |
Pharmaceutical compositions comprising arsenic trioxide for the treatment of non-Hodgkin's lymphoma
|
|
US6632823B1
(en)
|
1997-12-22 |
2003-10-14 |
Merck & Co., Inc. |
Substituted pyridine compounds useful as modulators of acetylcholine receptors
|
|
US6262116B1
(en)
|
1998-01-23 |
2001-07-17 |
Sloan-Kettering Institute For Cancer Research |
Transcription therapy for cancers
|
|
DE69939900D1
(de)
|
1998-06-05 |
2008-12-24 |
Nutrinia Ltd |
Insulin angereichertes säuglingsnährpräparat
|
|
AUPP466598A0
(en)
|
1998-07-14 |
1998-08-06 |
University Of Newcastle Research Associates Limited, The |
Product and process
|
|
US20040110822A1
(en)
|
1998-07-14 |
2004-06-10 |
The University Of Newcastle Research Associates |
Anhydride modified cantharidin analogues useful in the treatment of cancer
|
|
WO2000008015A2
(en)
|
1998-08-07 |
2000-02-17 |
Applied Research Systems Ars Holding N.V. |
Fsh mimetics for the treatment of infertility
|
|
US20020151515A1
(en)
|
1999-06-18 |
2002-10-17 |
Roberts Bruce L. |
Preparation and use of superior vaccines
|
|
US6949624B1
(en)
|
1999-08-03 |
2005-09-27 |
The United States Of America As Represented By The Department Of Health And Human Services |
Cloning of the human nuclear receptor co-repressor gene
|
|
BR0014254A
(pt)
|
1999-09-08 |
2002-08-27 |
Sloan Kettering Inst Cancer |
Nova classe de agentes de citodiferenciação e inibidores de desacetilase de histona, e métodos de uso dos mesmos
|
|
US7605185B2
(en)
|
1999-11-23 |
2009-10-20 |
Gerhart Graupner |
Treatment of arrhythmia by retinoids affecting signal transduction
|
|
AU2001243253A1
(en)
|
2000-02-24 |
2001-09-03 |
Biocryst Pharmaceuticals, Inc. |
Prodrugs of substituted cyclopentane and cyclopentene compounds useful as neuraminidase inhibitors
|
|
JP4518627B2
(ja)
|
2000-03-14 |
2010-08-04 |
旭化成イーマテリアルズ株式会社 |
ヒドロキシポリアミド
|
|
JP2003528074A
(ja)
|
2000-03-24 |
2003-09-24 |
メチルジーン インコーポレイテッド |
ヒストン脱アセチル化酵素の阻害剤
|
|
DE10038043B4
(de)
|
2000-08-02 |
2006-09-07 |
Walter, Michael, Dr. |
Phamakologisch wirksame Substanz zur Behandlung kardiovaskulärer Erkrankungen
|
|
PE20020354A1
(es)
|
2000-09-01 |
2002-06-12 |
Novartis Ag |
Compuestos de hidroxamato como inhibidores de histona-desacetilasa (hda)
|
|
WO2002024680A1
(en)
|
2000-09-21 |
2002-03-28 |
Smithkline Beecham P.L.C. |
Imidazole derivatives as raf kinase inhibitors
|
|
WO2002028387A1
(en)
|
2000-10-03 |
2002-04-11 |
Oncopharmaceutical, Inc. |
Inhibitors of angiogenesis and tumor growth for local and systemic administration
|
|
AU2001296661A1
(en)
|
2000-10-06 |
2002-04-15 |
Michigan State University |
Divinyl ether synthase gene and protein, and uses thereof
|
|
CN1213050C
(zh)
|
2000-11-23 |
2005-08-03 |
拜尔公司 |
氧杂双环[2.2.1]庚烷衍生物，其制备方法和作为农药的用途
|
|
US20020177692A1
(en)
|
2001-04-16 |
2002-11-28 |
Myriad Genetics, Incorporated |
BCL-XL-interacting protein and use thereof
|
|
US20030166531A1
(en)
|
2001-02-16 |
2003-09-04 |
Genetics Institute, Inc. |
Methods for modulating an immune response by modulating the interaction between CTLA4 and PP2A
|
|
AUPR392301A0
(en)
|
2001-03-23 |
2001-04-26 |
University Of Newcastle Research Associates Limited, The |
Protein phosphatase inhibitors
|
|
US20040253637A1
(en)
|
2001-04-13 |
2004-12-16 |
Biosite Incorporated |
Markers for differential diagnosis and methods of use thereof
|
|
US6905669B2
(en)
|
2001-04-24 |
2005-06-14 |
Supergen, Inc. |
Compositions and methods for reestablishing gene transcription through inhibition of DNA methylation and histone deacetylase
|
|
DE10122898A1
(de)
|
2001-05-11 |
2002-11-14 |
Haarmann & Reimer Gmbh |
Verwendung von Hydroxyflavanonen zur Maskierung des bitteren Geschmacks
|
|
US20070015144A9
(en)
|
2001-05-25 |
2007-01-18 |
Genset, S.A. |
Human cDNAs and proteins and uses thereof
|
|
US7528274B2
(en)
|
2001-08-03 |
2009-05-05 |
The United States Of America As Represented By The Department Of Health And Human Services |
Acylthiols and component thiol compositions as anti-HIV and anti-retroviral agents
|
|
US20040010045A1
(en)
|
2001-09-07 |
2004-01-15 |
Taolin Yi |
Therapeutic compositions comprised of pentamidine and methods of using same to treat cancer
|
|
US7179450B2
(en)
|
2001-09-20 |
2007-02-20 |
Medi-Physics, Inc. |
Methods for in vivo evaluation of pulmonary physiology and/or function using NMR signals of polarized Xe
|
|
EP1443928B1
(en)
|
2001-10-16 |
2011-07-27 |
Sloan-Kettering Institute For Cancer Research |
Treatment of neurodegenerative diseases and cancer of the brain
|
|
NZ544689A
(en)
|
2001-11-06 |
2007-08-31 |
Novartis Ag |
Cyclooxygenase-2 inhibitor/histone deacetylase inhibitor combination
|
|
AU2002353845A1
(en)
|
2001-11-23 |
2003-06-10 |
Eli Lilly And Company |
Prodrugs of excitatory amino acids
|
|
JP2004035408A
(ja)
|
2002-02-15 |
2004-02-05 |
Chiron Corp |
テザシタビンを含有する安定な組成物
|
|
US7488712B2
(en)
|
2002-02-20 |
2009-02-10 |
Kyushu Institute Of Technology |
Histone deacetylase inhibitors and methods for producing the same
|
|
US7148257B2
(en)
|
2002-03-04 |
2006-12-12 |
Merck Hdac Research, Llc |
Methods of treating mesothelioma with suberoylanilide hydroxamic acid
|
|
US7456219B2
(en)
|
2002-03-04 |
2008-11-25 |
Merck Hdac Research, Llc |
Polymorphs of suberoylanilide hydroxamic acid
|
|
CA2478587C
(en)
|
2002-03-08 |
2011-05-17 |
Basf Aktiengesellschaft |
Fungicidal mixtures based on prothioconazole and containing an insecticide
|
|
US6809118B2
(en)
|
2002-07-25 |
2004-10-26 |
Yih-Lin Chung |
Methods for therapy of radiation cutaneous syndrome
|
|
IL149404A0
(en)
|
2002-04-29 |
2002-11-10 |
Yissum Res Dev Co |
METHODS AND COMPOSITIONS FOR MODULATING β-CATENIN PHOSPHORYLATION
|
|
WO2003092616A2
(en)
|
2002-05-01 |
2003-11-13 |
The Cleveland Clinic Foundation |
Therapeutic compositions comprised of pentamidine and methods of using same to treat cancer
|
|
US20040087531A1
(en)
|
2002-05-16 |
2004-05-06 |
Adam Telerman |
Compositions and methods for the treatment of cancer
|
|
KR20060010709A
(ko)
|
2002-09-23 |
2006-02-02 |
쉐링 코포레이션 |
사이클린 의존성 키나제 억제제로서의 신규한 이미다조피라진
|
|
US7154002B1
(en)
|
2002-10-08 |
2006-12-26 |
Takeda San Diego, Inc. |
Histone deacetylase inhibitors
|
|
US8404716B2
(en)
|
2002-10-15 |
2013-03-26 |
Celgene Corporation |
Methods of treating myelodysplastic syndromes with a combination therapy using lenalidomide and azacitidine
|
|
US7189740B2
(en)
|
2002-10-15 |
2007-03-13 |
Celgene Corporation |
Methods of using 3-(4-amino-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myelodysplastic syndromes
|
|
AU2003291736A1
(en)
|
2002-11-05 |
2004-06-03 |
Cell Signaling Technology, Inc. |
Methods and materials for examining pathways associated with glioblastoma progression
|
|
GB0226855D0
(en)
|
2002-11-18 |
2002-12-24 |
Queen Mary & Westfield College |
Histone deacetylase inhibitors
|
|
ES2367430T3
(es)
|
2002-12-23 |
2011-11-03 |
Wyeth Llc |
Anticuerpos contra pd-1 y sus usos.
|
|
US20040197888A1
(en)
|
2002-12-31 |
2004-10-07 |
Armour Christopher D. |
Alternatively spliced isoforms of histone deacetylase 3 (HDAC3)
|
|
WO2004064727A2
(en)
|
2003-01-16 |
2004-08-05 |
Georgetown University |
Method of cancer treatment using hdac inhibitors
|
|
US8802116B2
(en)
|
2003-02-27 |
2014-08-12 |
Novasel Australia Pty. Ltd. |
Poloxamer emulsion preparations
|
|
EP1601965A4
(en)
|
2003-03-12 |
2010-11-10 |
Samaritan Pharmaceuticals Inc |
SIMULATION OF NEUROLOGICAL DISEASES WITH ANIMAL MODEL
|
|
WO2004087153A2
(en)
|
2003-03-28 |
2004-10-14 |
Chiron Corporation |
Use of organic compounds for immunopotentiation
|
|
US7842835B2
(en)
|
2003-07-07 |
2010-11-30 |
Georgetown University |
Histone deacetylase inhibitors and methods of use thereof
|
|
US7514438B2
(en)
|
2003-08-13 |
2009-04-07 |
Amgen, Inc. |
Melanin concentrating hormone receptor antagonist
|
|
WO2005025620A2
(en)
|
2003-08-13 |
2005-03-24 |
Pharmacia Corporation |
Combination therapy with inhibitors of inducible nitric oxide synthase and alkylating agents
|
|
US7378409B2
(en)
|
2003-08-21 |
2008-05-27 |
Bristol-Myers Squibb Company |
Substituted cycloalkylamine derivatives as modulators of chemokine receptor activity
|
|
WO2005018673A1
(en)
|
2003-08-21 |
2005-03-03 |
Osaka University |
Pharmaceutical composition for preventing or remedying cardiac hypertrophy and cardiocascular disease caused thereby
|
|
US7094193B2
(en)
|
2003-08-28 |
2006-08-22 |
Philip Morris Usa Inc. |
High speed laser perforation of cigarette tipping paper
|
|
US20070004771A1
(en)
|
2003-10-06 |
2007-01-04 |
Glaxo Group Limited |
Preparation of 1,6,7-trisubstituted azabenzimidazoles as kinase inhibitors
|
|
US20070208166A1
(en)
|
2003-10-24 |
2007-09-06 |
Exelixis, Inc. |
Tao Kinase Modulators And Method Of Use
|
|
US20050182011A1
(en)
|
2003-11-13 |
2005-08-18 |
Eric Olson |
Inhibition of TRP channels as a treatment for cardiac hypertrophy and heart failure
|
|
GB0328157D0
(en)
|
2003-12-04 |
2004-01-07 |
Imp College Innovations Ltd |
Compounds
|
|
US20060018970A1
(en)
|
2003-12-12 |
2006-01-26 |
Myogen, Inc. |
Enoximone formulations and their use in the treatment of cardiac hypertrophy and heart failure
|
|
US8652502B2
(en)
|
2003-12-19 |
2014-02-18 |
Cordis Corporation |
Local vascular delivery of trichostatin A alone or in combination with sirolimus to prevent restenosis following vascular injury
|
|
US20050282893A1
(en)
|
2004-01-30 |
2005-12-22 |
Au Jessie L |
Methods and compositions for using suramin, pentosan, polysulfate, telomerase antisense and telomerase inhibitors
|
|
EP1715870A1
(en)
|
2004-02-02 |
2006-11-02 |
Myogen, Inc. |
Inhibition of protein kinase c-related kinase (prk) as a treatment for cardiac hypertrophy and heart failure
|
|
US7253204B2
(en)
|
2004-03-26 |
2007-08-07 |
Methylgene Inc. |
Inhibitors of histone deacetylase
|
|
FR2872704B1
(fr)
|
2004-07-12 |
2007-11-02 |
Laurent Schwartz |
Pluritherapie contre le cancer
|
|
CN1586500A
(zh)
|
2004-07-19 |
2005-03-02 |
俞锋 |
治疗肿瘤的斑蝥酸钠注射剂及其制备方法
|
|
JP5070052B2
(ja)
|
2004-08-17 |
2012-11-07 |
ザ・ジョンズ・ホプキンス・ユニバーシティ |
Ｐｄｅ５阻害剤組成物及び心臓疾患を治療する方法
|
|
WO2006052842A2
(en)
|
2004-11-09 |
2006-05-18 |
The Trustees Of The University Of Pennsylvania |
Methods for diagnosis of myelodysplastic syndromes (mds)
|
|
KR100677149B1
(ko)
|
2004-11-12 |
2007-02-02 |
삼성전자주식회사 |
잉크 조성물
|
|
AU2006228957A1
(en)
|
2005-04-01 |
2006-10-05 |
Methylgene Inc. |
Inhibitors of histone deacetylase
|
|
CN1304396C
(zh)
|
2005-04-08 |
2007-03-14 |
中山大学 |
斑蝥素衍生物及其制备方法
|
|
EP3530736A3
(en)
|
2005-05-09 |
2019-11-06 |
ONO Pharmaceutical Co., Ltd. |
Human monoclonal antibodies to programmed death 1 (pd-1) and methods for treating cancer using anti-pd-1 antibodies alone or in combination with other immunotherapeutics
|
|
GB0511266D0
(en)
|
2005-06-02 |
2005-07-13 |
Trust |
Chemical compounds
|
|
KR101704734B1
(ko)
|
2005-07-01 |
2017-02-09 |
이. 알. 스퀴부 앤드 선즈, 엘.엘.씨. |
예정 사멸 리간드 1 (피디-엘1)에 대한 인간 모노클로날 항체
|
|
WO2007014029A2
(en)
|
2005-07-22 |
2007-02-01 |
The Regents Of The University Of Colorado, A Body Corporate |
Yin yang 1 as a treatment for cardiac hypertrophy and heart failure
|
|
CA2617636A1
(en)
|
2005-08-10 |
2007-02-22 |
Novartis Ag |
Use of histone deacetylase inhibitors for treating cardiac hypertrophy and heart failure
|
|
EP2275096A3
(en)
|
2005-08-26 |
2011-07-13 |
Braincells, Inc. |
Neurogenesis via modulation of the muscarinic receptors
|
|
US20070092553A1
(en)
|
2005-10-21 |
2007-04-26 |
Pfab Lp |
Compositions and methods of making rapidly dissolving lonically masked formulations
|
|
CN101374801B
(zh)
|
2005-12-19 |
2014-07-02 |
梅特希尔基因公司 |
用于增强抗真菌剂活性的组蛋白脱乙酰酶抑制剂
|
|
WO2007092414A2
(en)
|
2006-02-06 |
2007-08-16 |
Lixte Biotechnology Holdings, Inc. |
Use of phosphatases to treat tumors overexpressing n-cor
|
|
CA2648804C
(en)
|
2006-04-07 |
2014-05-27 |
Methylgene Inc. |
Benzamide derivatives as inhibitors of histone deacetylase
|
|
PE20080695A1
(es)
|
2006-04-27 |
2008-06-28 |
Banyu Pharma Co Ltd |
Derivados de dihidropirazolopirimidinona como inhibidores de quinasa weel
|
|
US20090018142A9
(en)
|
2006-05-02 |
2009-01-15 |
Zhengping Zhuang |
Use of phosphatases to treat tumors overexpressing N-CoR
|
|
WO2008030617A2
(en)
|
2006-09-07 |
2008-03-13 |
Stemline Therapeutics, Inc. |
Cancer therapy with cantharidin and cantharidin analogs
|
|
ES2423482T3
(es)
|
2006-09-08 |
2013-09-20 |
Institut Gustave Roussy (Igr) |
Inhibidores de proteína fosfatasa 1, de GADD34 y del complejo de proteína fosfatasa 1/GADD34, y usos de los mismos combinados con etopósido o mitomicina C
|
|
US20080097561A1
(en)
|
2006-10-18 |
2008-04-24 |
Medcool, Inc. |
Dual cycle thermal system and method of use
|
|
EP2086534A4
(en)
|
2006-11-15 |
2010-06-02 |
Genetic Technologies Ltd |
COMPOUNDS, COMPOSITIONS AND METHOD FOR CONTROLLING SWIVELY PESTS
|
|
BRPI0806365B8
(pt)
|
2007-02-06 |
2021-05-25 |
Lixte Biotechnology Holdings Inc |
composto, uso do composto, composição farmacêutica e uso da composição farmacêutica
|
|
US8413445B2
(en)
|
2007-05-11 |
2013-04-09 |
General Electric Company |
Method and system for porous flame holder for hydrogen and syngas combustion
|
|
PT2170959E
(pt)
|
2007-06-18 |
2014-01-07 |
Merck Sharp & Dohme |
Anticorpos para o receptor humano de morte programada pd-1
|
|
US20090035292A1
(en)
|
2007-08-03 |
2009-02-05 |
Kovach John S |
Use of phosphatases to treat neuroblastomas and medulloblastomas
|
|
CA2700857C
(en)
|
2007-10-01 |
2016-08-02 |
John S. Kovach |
Hdac inhibitors
|
|
JP5069091B2
(ja)
|
2007-12-12 |
2012-11-07 |
三菱電機株式会社 |
監視カメラおよび監視カメラシステム
|
|
PT2242773T
(pt)
|
2008-02-11 |
2017-09-15 |
Cure Tech Ltd |
Anticorpos monoclonais para o tratamento de tumores
|
|
US8168757B2
(en)
|
2008-03-12 |
2012-05-01 |
Merck Sharp & Dohme Corp. |
PD-1 binding proteins
|
|
WO2010014141A1
(en)
|
2008-08-01 |
2010-02-04 |
Lixte Biotechnology, Inc. |
Methods for regulating cell mitosis by inhibiting serine/threonine phosphatase
|
|
WO2010147612A1
(en)
|
2009-06-18 |
2010-12-23 |
Lixte Biotechnology, Inc. |
Methods of modulating cell regulation by inhibiting p53
|
|
US8227473B2
(en)
|
2008-08-01 |
2012-07-24 |
Lixte Biotechnology, Inc. |
Oxabicycloheptanes and oxabicycloheptenes, their preparation and use
|
|
WO2010014220A1
(en)
|
2008-08-01 |
2010-02-04 |
Lixte Biotechnology, Inc. |
Neuroprotective agents for the prevention and treatment of neurodegenerative diseases
|
|
WO2010098788A2
(en)
|
2008-08-25 |
2010-09-02 |
Amplimmune, Inc. |
Pd-i antagonists and methods for treating infectious disease
|
|
EA201500417A1
(ru)
|
2008-08-25 |
2015-11-30 |
Эмплиммьюн, Инк. |
Композиции антагонистов pd-1 и способы применения
|
|
CN101367783A
(zh)
|
2008-10-10 |
2009-02-18 |
中国科学技术大学 |
5-羟甲基糠醛的制备方法
|
|
MX356367B
(es)
|
2008-12-09 |
2018-05-25 |
Genentech Inc |
Anticuerpos anti-pd-l1 y su uso para mejorar la funcion de celulas t.
|
|
WO2010089411A2
(en)
|
2009-02-09 |
2010-08-12 |
Universite De La Mediterranee |
Pd-1 antibodies and pd-l1 antibodies and uses thereof
|
|
GB0903325D0
(en)
|
2009-02-26 |
2009-04-08 |
Univ Aberdeen |
Antibody molecules
|
|
US20120135522A1
(en)
|
2009-06-18 |
2012-05-31 |
Kovach John S |
Methods of modulating cell regulation by inhibiting p53
|
|
EP2504028A4
(en)
|
2009-11-24 |
2014-04-09 |
Amplimmune Inc |
SIMULTANEOUS INHIBITION OF PD-L1 / PD-L2
|
|
WO2011094683A2
(en)
|
2010-01-29 |
2011-08-04 |
H. Lee Moffitt Cancer Center And Research Institute, Inc. |
Method of identifying myelodysplastic syndromes
|
|
AU2011243947A1
(en)
|
2010-04-23 |
2012-12-06 |
Piramal Enterprises Limited |
Nitric oxide releasing prodrugs of therapeutic agents
|
|
US20140235649A1
(en)
|
2011-05-24 |
2014-08-21 |
Lixte Biotechnology, Inc. |
Use of phosphatase inhibitors or histone deacetylase inhibitors to treat diseases characterized by loss of protein function
|
|
US9345705B2
(en)
|
2011-09-15 |
2016-05-24 |
Merck Sharp & Dohme Corp. |
Compositions and methods for treating cancer
|
|
US20150005250A1
(en)
|
2011-10-13 |
2015-01-01 |
H. Lee Moffitt Cancer Center And Research Institute, Inc. |
Telomerase reverse transcriptase deficiency as diagnostic marker of myelodysplastic syndrome
|
|
EP2857385B1
(en)
|
2012-06-01 |
2017-08-02 |
Taisho Pharmaceutical Co., Ltd. |
Prodrug of fluorine-containing amino acid
|
|
EP2867239A4
(en)
|
2012-06-29 |
2015-12-23 |
Lixte Biotechnology Inc |
OXABICYCLOHEPTANES AND OXABICYCLOHEPTENES FOR THE TREATMENT OF DIABETES
|
|
WO2014005080A1
(en)
|
2012-06-29 |
2014-01-03 |
Lixte Biotechnology, Inc. |
Oxabicycloheptanes and oxabicycloheptenes for the treatment of reperfusion injury
|
|
US9738933B2
(en)
|
2012-12-05 |
2017-08-22 |
H. Lee Moffitt Cancer Center And Research Institute, Inc. |
RNF41 as a biomarker predicting response to lenalidomide in non-del(5q) MDS
|
|
WO2014137741A1
(en)
|
2013-03-05 |
2014-09-12 |
Lixte Biotechnology, Inc. |
Hdac inhibitors for treating traumatic brain injury
|
|
WO2014149494A1
(en)
|
2013-03-15 |
2014-09-25 |
Lixte Biotechnology, Inc. |
Sanguinarine analog pp2c inhibitors for cancer treatment
|
|
KR20160004299A
(ko)
|
2013-04-09 |
2016-01-12 |
릭스트 바이오테크놀로지, 인코포레이티드 |
옥사바이시클로헵탄류 및 옥사바이시클로헵텐류의 제형
|
|
JP2016538281A
(ja)
|
2013-11-15 |
2016-12-08 |
リクスト・バイオテクノロジー，インコーポレイテッド |
血液脳関門を通過するタンパク質ホスファターゼ阻害剤
|
|
US9051332B1
(en)
|
2013-11-20 |
2015-06-09 |
Transitions Optical, Inc. |
Photochromic indeno-fused ring pyran compounds
|
|
UA122479C2
(uk)
|
2014-01-24 |
2020-11-25 |
Дана-Фарбер Кенсер Інстітьют, Інк. |
Виділена молекула антитіла, яка зв’язується з людським білком програмованої смерті-1 (pd-1)
|
|
CA2940097A1
(en)
|
2014-04-28 |
2015-11-05 |
Alembic Pharmaceuticals Limited |
Novel polymorphic forms of vortioxetine and its pharmaceutically acceptable salts
|
|
US20170136008A1
(en)
|
2014-06-20 |
2017-05-18 |
Lixte Biotechnology, Inc. |
Oxabicycloheptanes and oxabicycloheptenes for the treatment of ovarian cancer
|
|
WO2016014778A1
(en)
|
2014-07-24 |
2016-01-28 |
H. Lee Moffitt Cancer Center And Research Institute, Inc. |
Protein phosphatase 2a inhibitors for treating myelodysplastic syndromes
|
|
US20160074390A1
(en)
|
2014-09-12 |
2016-03-17 |
Lixte Biotechnology, Inc. |
Human dosing of phosphatase inhibitor
|
|
US9994584B2
(en)
|
2014-10-15 |
2018-06-12 |
Lixte Biotechnology, Inc. |
Process of synthesizing 3-(4-methylpiperazine-1-carbonyl)-7-oxabicyclo[2.2.1] heptane-2-carboxylic acid
|
|
MX382044B
(es)
|
2015-02-19 |
2025-03-13 |
Lixte Biotechnology Inc |
Oxabicicloheptanos y oxabicicloheptenos para el tratamiento de trastornos depresivos y de estrés.
|
|
HRP20201334T1
(hr)
*
|
2015-04-17 |
2020-11-27 |
Bristol-Myers Squibb Company |
Kompozicije koje sadrže kombinaciju ipilimumaba i nivolumaba
|
|
JP7187023B6
(ja)
|
2015-05-15 |
2023-01-05 |
リクスト・バイオテクノロジー，インコーポレイテッド |
オキサビシクロヘプタンプロドラッグ
|
|
CA2999070A1
(en)
|
2015-09-17 |
2017-03-23 |
Novartis Ag |
Car t cell therapies with enhanced efficacy
|
|
EP3407887B1
(en)
|
2016-01-27 |
2021-09-01 |
Lixte Biotechnology, Inc. |
Clinical regimen for treating myelodysplastic syndrome with phosphatase inhibitor
|
|
WO2017176289A1
(en)
|
2016-04-08 |
2017-10-12 |
Celgene Corporation |
Uses of lenalidomide and car t-cells
|
|
AU2017370731B2
(en)
|
2016-12-08 |
2022-06-02 |
Lixte Biotechnology, Inc. |
Oxabicycloheptanes for modulation of immune response
|
|
US20210275521A1
(en)
|
2017-12-05 |
2021-09-09 |
Lixte Biotechnology, Inc. |
Oxabicycloheptanes for treatment of secondary acute myeloid leukemia
|
|
US20210379106A1
(en)
|
2018-06-14 |
2021-12-09 |
Lixte Biotechnology, Inc. |
Oxabicycloheptanes for enhancing car t cell function
|
|
RU201598U1
(ru)
|
2020-05-14 |
2020-12-22 |
Андрей Владимирович Дмитриев |
Безреагентная испарительная градирня
|
|
KR20230136624A
(ko)
|
2021-01-19 |
2023-09-26 |
릭스트 바이오테크놀로지, 인코포레이티드 |
소세포 폐암의 치료를 위한 옥사비시클로헵탄
|
|
TW202342039A
(zh)
|
2022-01-04 |
2023-11-01 |
美商利克斯特生物科技公司 |
用於治療癌症或預防、抑制或降低癌症轉移風險之組成物及方法
|